Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 478,725
  • Shares Outstanding, K 57,059
  • Annual Sales, $ 177,980 K
  • Annual Income, $ -76,910 K
  • 60-Month Beta 1.46
  • Price/Sales 4.72
  • Price/Cash Flow N/A
  • Price/Book 3.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.27
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.29
  • Prior Year 0.25
  • Growth Rate Est. (year over year) -208.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.01 +19.69%
on 03/11/19
9.30 -9.78%
on 03/12/19
+1.07 (+14.62%)
since 02/22/19
3-Month
5.20 +61.35%
on 12/24/18
9.30 -9.78%
on 03/12/19
+2.97 (+54.80%)
since 12/21/18
52-Week
5.20 +61.35%
on 12/24/18
11.60 -27.67%
on 06/20/18
-3.29 (-28.17%)
since 03/22/18

Most Recent Stories

More News
Akebia Therapeut Shares Up 27.1% Since SmarTrend's Buy Recommendation (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on February 22nd, 2019 at $6.97. In approximately 4 weeks, Akebia Therapeut has returned 27.12% as of today's recent price of $8.86.

AKBA : 8.39 (-3.56%)
Relatively Good Performance Detected in Shares of Cytokinetics Inc in the Biotechnology Industry (CYTK , AKBA , NTRA , UTHR , MGNX )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

NTRA : 19.68 (-3.95%)
CYTK : 8.75 (-1.02%)
AKBA : 8.39 (-3.56%)
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights

--- First regulatory submission for vadadustat expected in 2019 in Japan, following positive top-line results from pivotal phase 3 studies in Japanese subjects with anemia due to chronic kidney disease...

AKBA : 8.39 (-3.56%)
Accelerated Clinical Trials Bridging Gateway to Latest Treatments for Cancer Patients

Cancer research has for years been steadily gaining ground on its way to managing, curing and even preventing the various forms of this insidious disease. Both public and private money continues to flow...

ELAN : 32.72 (+0.74%)
AKBA : 8.39 (-3.56%)
PFE : 41.85 (-1.18%)
MBRX : 1.32 (-0.75%)
SEEL : 2.59 (+15.11%)
Akebia Therapeut Rises 7.08% on Heavy Volume: Watch For Potential Pullback

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $7.02 to a high of $9.06. Yesterday, the shares gained 7.1%, which took the trading range above the 3-day high of...

AKBA : 8.39 (-3.56%)
Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKBA : 8.39 (-3.56%)
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast

Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced...

AKBA : 8.39 (-3.56%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11...

AKBA : 8.39 (-3.56%)
Biotechnology Companies Ramp up Funding as Deadly Diseases Come Into the Spotlight

Biotechnology is rapidly and continually evolving each year with new innovative therapies and drugs. The companies within the industry are researching and developing new efficient ways to effectively treat...

BTHCF : 0.1880 (+1.62%)
CNAT : 1.28 (-56.01%)
AGN.CN : 0.255 (+6.25%)
RMTI : 5.79 (-8.96%)
AKBA : 8.39 (-3.56%)
KDMN : 2.77 (-6.42%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11...

AKBA : 8.39 (-3.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More Share

Trade AKBA with:

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 9.17
1st Resistance Point 8.78
Last Price 8.39
1st Support Level 8.19
2nd Support Level 7.99

See More

52-Week High 11.60
Fibonacci 61.8% 9.16
Fibonacci 50% 8.40
Last Price 8.39
Fibonacci 38.2% 7.64
52-Week Low 5.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar